After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ ...
Rarely does the FDA publicly release its reasoning for rejecting a potential new drug. But for DC-based Vanda Pharmaceuticals’ gastroparesis drug, the FDA on ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Orchid Security, an emerging leader in identity-first security orchestration, today announced it has raised $36 million in seed funding. Co-led by Team8 and Intel Capital, with the support of ...
After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, M.D., is calling out the regulatory agency for a “disturbing pattern ...
Vanda called the attention of FDA Commissioner Robert Califf to what it termed the “sentiment that the agency avoids public scrutiny of its decisions.” Vanda Pharmaceuticals on Wednesday sent a letter ...
Step 3: Search it up When a botanist suspects a species is new to science, it's the start of a long journey to find out. The team began a search to compare the orchid from Norfolk Island with ...
WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. Vanda Logo (PRNewsfoto/Vanda ...
Looking around at the hundreds of orchids in bloom on the back patio of her Weston home, Sara Singer is hard-pressed to pick a favorite from her beloved collection. There are the highly prized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback